Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Payables: 2016-2025

Historic Payables for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $13.6 million.

  • Rhythm Pharmaceuticals' Payables rose 178.92% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.9 million, marking a year-over-year increase of 146.30%. This contributed to the annual value of $12.3 million for FY2024, which is 152.36% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Payables stood at $13.6 million for Q3 2025, which was down 14.71% from $16.0 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Payables high stood at $16.0 million for Q2 2025, and its period low was $3.8 million during Q3 2023.
  • Moreover, its 3-year median value for Payables was $8.4 million (2023), whereas its average is $9.2 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 45.81% in 2024, then soared by 251.79% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Payables (Quarterly) stood at $5.7 million in 2021, then fell by 16.38% to $4.8 million in 2022, then climbed by 1.83% to $4.9 million in 2023, then soared by 152.36% to $12.3 million in 2024, then skyrocketed by 178.92% to $13.6 million in 2025.
  • Its Payables was $13.6 million in Q3 2025, compared to $16.0 million in Q2 2025 and $11.9 million in Q1 2025.